SAN FRANCISCO, June 19, 2017 (GLOBE NEWSWIRE) -- Today ProLynx LLC announced a collaboration with Daiichi Sankyo Company, Limited to evaluate its drug delivery linker technology in the eye.
In the ProLynx half-life extension platform technology, a drug is tethered to a carrier by a self-cleaving b-eliminative linker that is pre-programmed to release the drug at a pre-determined rate. After injection, the drug is slowly released from the carrier depot. The ProLynx-Daiichi Sankyo collaboration will evaluate the utility of the releasable linker technology in half-life extension of small-molecule drugs after intravitreal injection.
Daniel Santi, co-founder and President of ProLynx, said: “There are numerous opportunities for our half-life extension technology in localized delivery of drugs. Small, local compartments – such as the eye – should retain therapeutic concentrations of the released free drug for prolonged periods before the drug is distributed systemically.”
About ProLynx. ProLynx LLC is a privately held biotechnology company developing proprietary drug delivery systems for half-life extension of proteins, peptides and small molecules. The company is seeking to apply its technology to extend half-lives of drug candidates of pharmaceutical companies, and to improve properties of off-patent therapeutics. ProLynx has a monthly GLP-1 receptor agonist and a subcutaneous long-acting octreotide in its pre-clinical portfolio, and a PEG~SN-38 in Phase 1 clinical trials. The company is located in San Francisco, CA. Further information about the company and its capabilities go to www.ProLynxllc.com.
About Daiichi Sankyo. Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases. For more information, please visit: www.daiichisankyo.com.